A Study of ADRX-0706 in Select Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the safety, tolerability, and
pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select
advanced solid tumors.